Calculating Lung Shunt Fraction

Estimate lung shunt fraction (LSF) from pre-treatment 99mTc-MAA counts for radioembolization planning. This tool applies background correction and reports LSF percentage, qualitative risk tier, and estimated lung dose when planned activity and lung mass are provided.

Expert Guide to Calculating Lung Shunt Fraction in Y-90 Radioembolization Planning

Lung shunt fraction (LSF) is one of the most important safety variables in transarterial radioembolization workup, especially when yttrium-90 (Y-90) microspheres are being considered for hepatocellular carcinoma, cholangiocarcinoma, or metastatic liver disease. In practical terms, LSF estimates what portion of injected surrogate particles bypasses hepatic microcirculation and reaches the pulmonary vascular bed. If the estimate is too high, excessive radiation to the lungs can occur. That is why LSF is not just a technical number in a report. It directly influences treatment eligibility, activity prescription, and whether staged or alternative strategies are safer.

Most centers estimate LSF using technetium-99m macroaggregated albumin (99mTc-MAA) delivered through a planned treatment catheter position. After imaging, regions of interest are drawn over lung and liver counts. The classic formula is:

LSF = Lung counts / (Lung counts + Liver counts)
If background correction is used, corrected counts should replace raw counts in the formula.

This calculator implements that standard approach. It also allows optional background subtraction and optional lung dose estimation using a commonly used partition-model relationship: Lung Dose (Gy) = Activity (GBq) x 50 x LSF / Lung Mass (kg). While simplified, this equation is clinically useful for first-pass safety checks during planning.

Why LSF Matters Clinically

• Patient safety: Elevated shunting increases pulmonary irradiation risk.
• Dose planning: Activity may need reduction when LSF is high.
• Device-specific constraints: Product labeling and institutional protocols may differ in how limits are applied.
• Route optimization: Catheter position and embolization strategy can affect shunting and may be adjusted between mapping and treatment.

Step-by-Step Calculation Workflow

1. Perform angiographic mapping and inject 99mTc-MAA from intended treatment position.
2. Acquire planar imaging and or SPECT/CT per institutional protocol.
3. Draw liver and lung ROIs carefully, minimizing overlap and accounting for extrahepatic activity.
4. Record raw counts from each compartment.
5. Apply background correction if your protocol requires it.
6. Compute LSF with corrected values.
7. If prescribing activity, estimate lung dose and compare with accepted safety constraints.
8. Document method, ROI logic, corrections, and assumptions in the final report.

Interpreting Results: Practical Threshold Thinking

Interpretation should always follow product-specific labeling and your multidisciplinary protocol. Historically, clinicians often communicated LSF bands such as below 10%, 10% to 20%, and above 20% for quick risk discussion. Modern practice increasingly translates LSF into estimated lung absorbed dose, because dose offers a more individualized safety metric than percentage alone. Still, both values are often reported side by side.

LSF Range	Common Planning Interpretation	Typical Operational Response
< 10%	Usually favorable shunt profile	Proceed with planned activity if other constraints are acceptable
10% to 20%	Intermediate caution zone	Consider activity adjustment and explicit lung dose calculation
> 20%	High shunt concern in many historical protocols	Re-evaluate mapping, catheter position, activity, staging, or alternate treatment

The table above reflects widely used practical bands rather than a universal rule. In contemporary dosimetry, many teams prioritize lung absorbed dose ceilings rather than only the shunt percentage. This is especially important because two patients with identical LSF can have different risk if prescribed activity and lung mass differ.

Planar vs SPECT/CT: Why Modality Choice Can Shift LSF

Planar imaging remains common and accessible, but several studies have shown that planar techniques can overestimate shunting compared with SPECT/CT-based compartment analysis due to overlap, attenuation effects, and reduced anatomic specificity. This is one reason many high-volume centers use SPECT/CT whenever available for more robust dosimetry decisions.

Metric	Planar ROI (Typical Reports)	SPECT/CT (Typical Reports)
LSF estimate trend	Often higher due to overlap and scatter limitations	Often lower and anatomically better localized
Absolute difference seen in cohorts	Frequently reported in the low single digits to low teens (percentage points), depending on protocol and segmentation
Impact on treatment eligibility	Published cohorts report meaningful reclassification of candidates when moving from planar-only to SPECT/CT-informed evaluation

Importantly, no single number from one paper should be transplanted blindly across institutions. Scanner hardware, reconstruction settings, ROI conventions, and operator training all influence measured LSF. The best practice is internal standardization with periodic quality audits.

Common Technical Pitfalls That Distort LSF

• Non-matching catheter position: If mapping injection location differs from treatment position, shunt estimate may not represent actual therapy distribution.
• Inadequate extrahepatic assessment: Activity in stomach or bowel can alter interpretation and should trigger careful angiographic and imaging review.
• Poor ROI segmentation: Overly generous lung ROI or incomplete liver ROI biases the fraction upward.
• No documented background method: Inconsistent subtraction methods create inter-reader variability.
• Ignoring clinical context: Prior surgery, portal vein thrombosis, and advanced tumor vascularity may alter microsphere behavior.

How to Use This Calculator Responsibly

This calculator is designed as a transparent planning aid, not an autonomous decision engine. It is best used in the same session where counts are reviewed by nuclear medicine and interventional teams. For best reliability:

1. Use the exact counts from your validated workstation workflow.
2. Apply background correction consistently and document the method.
3. If lung dose is estimated, enter the activity and lung mass assumptions used by your institution.
4. Cross-check with product labeling, local policy, and multidisciplinary review.
5. If estimated values approach safety limits, escalate to detailed dosimetry review rather than relying on a quick estimate.

Worked Example

Suppose mapping yields raw lung counts of 125,000 and raw liver counts of 980,000. Background counts are 5,000 (lung) and 12,000 (liver). Corrected counts become 120,000 and 968,000. LSF is:

LSF = 120,000 / (120,000 + 968,000) = 0.1103, or 11.03%.

If planned activity is 2.5 GBq and assumed lung mass is 1.0 kg, estimated lung dose is: 2.5 x 50 x 0.1103 / 1.0 = 13.79 Gy. In many institutions, this may be acceptable, but final interpretation still depends on product-specific and cumulative dose limits.

Quality Assurance and Documentation Checklist

• Record mapping date, catheter position, and administered 99mTc-MAA activity.
• State acquisition type (planar, SPECT/CT, or hybrid workflow).
• Describe ROI boundaries and whether background correction was applied.
• Report LSF as both decimal and percentage.
• Report estimated lung dose and assumptions (activity, lung mass model).
• Include recommendation language tied to institutional and device guidance.

Authoritative References and Further Reading

• PubMed (.gov): Peer-reviewed literature on lung shunt fraction and radioembolization dosimetry
• National Cancer Institute (.gov): Clinical overview of radioembolization
• UCSF Radiology (.edu): Interventional radiology treatment context and patient-care framework

Final note: true risk estimation depends on complete patient context, including performance status, liver reserve, prior therapies, and intended treatment volume. Use LSF as a core safety input, then finalize decisions in a multidisciplinary framework that includes interventional radiology, nuclear medicine, medical oncology, and medical physics.